Claim Missing Document
Check
Articles

Found 3 Documents
Search

Improving Cytokines and HDL in Diabetic Wistar Rats by Using Combination of Curcumin and Metformin Dinanti, Fathia Kesuma; Mulyani, Sri Priyantini; Chodidjah, Chodidjah
Mutiara Medika: Jurnal Kedokteran dan Kesehatan Vol 23, No 1 (2023): January
Publisher : Universitas Muhammadiyah Yogyakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18196/mmjkk.v23i1.17031

Abstract

In type 2 diabetes mellitus, lipid profile is often found in the form of high-density lipoprotein (HDL) decrease. TNFa and IL-6 are proinflammatory cytokines that are elevated in the blood in many patients with diabetes mellitus. Turmeric is one of the natural ingredients that have anti-cholesterol and anti-inflammatory effects through the work of its active substance, curcumin. This study aims to evaluate the effect of turmeric extract combined with metformin on HDL, TNFa, and IL-6 levels in diabetic rats. Twenty-four Wistar rats were injected intraperitoneally with streptozotocin and niacinamide. The diabetic rats were divided into control, metformin, turmeric, and combination groups. The dose of metformin and turmeric were given, respectively, 45mg/KgBW/day and 200 mg/KgBW/day. At the same time, the combo group was given a half dose of each. Blood serum was taken to examine the HDL, IL-6, and TNFa levels. The levels of HDL, IL-6, and TNFain diabetic rats that received the combination of metformin and turmeric extract (p0.05) were the best among all the groups. It indicated that the combination of metformin and turmeric was better in increasing HDL and reducing IL-6 and TNFa levels better than metformin or turmeric extract alone.
Pengaruh Kombinasi Metformin dan Ekstrak Kunyit terhadap Kadar High Density Lipoprotein, Interleukin-6 dan Tumor Necrosis Factor-a Dinanti, Fathia Kesuma; Mulyani, Sri Priyantini; -, Chodidjah -
Jurnal Kesehatan Andalas Vol. 11 No. 3 (2022): Online November 2022
Publisher : Faculty of Medicine, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jka.v11i3.2074

Abstract

A  decrease in high-density lipoprotein (HDL) happens in type 2 diabetes mellitus. The cytokines TNFa and IL-6 are proinflammatory cytokines that are elevated in the blood in many patients with DM. Turmeric is one of the natural ingredients with antioxidant, anti-cholesterol, and anti-inflammatory properties through its active substance, curcumin. Objective: To prove the effectiveness of the combination of metformin and turmeric extract on HDL levels, TNFa levels, and IL-6 levels in Streptozotocin-Nicotinamide-induced Wistar rats. Methods: The study used a post-test-only controlled group design. The subjects were 24 male Wistar rats which were randomly divided into four groups, namely K1, K2, P1, and P2. The whole group was a type 2 DM model induced by streptozotocin-nicotinamide. Group K2 was given metformin 45mg/KgBW/day, group P1 was given turmeric extract at a dose of 200 mg/KgBW/day, and group P2 was given a combination of metformin and turmeric extract. On day 15, blood was drawn for HDL, IL-6, and TNFa examination. The data were analyzed using the one-way Anova test. Results: The mean HDL level in the P2 group (72,4±33,31) was the highest compared to the other three groups. The lowest mean TNFa level among the four groups was the P2 group (7,56±0,44). The lowest mean levels of IL-6 were obtained in the P2 group (58,82±2,15). One-way Anova test on HDL, IL-6, and TNFa levels showed a significant difference between groups with p-value = 0.000. Conclusion: The combination of metformin and turmeric extract can increase HDL levels and reduce IL-6 levels and TNFa levels better than giving metformin or turmeric extract alone.Keywords:  turmeric extract, HDL, IL-6, TNFa
Efek Anti-Inflamasi Tanaman Avicennia : Kajian Sistematik Dinanti, Fathia Kesuma; Madusari, Benny Diah; Hernanda, Ary Setya
Jurnal Biomedika dan Kesehatan Vol 8 No 2 (2025)
Publisher : Fakultas Kedokteran Universitas Trisakti

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Avicennia, commonly known as mangrove plants, has been traditionally used to treat various diseases, including cancer, malaria, asthma, rheumatism, and ulcers. This genus possesses a range of unique secondary metabolites, belonging to various classes, which play a crucial role in numerous pharmacological activities, including the regulation of inflammation. Although many research articles have been published on the pharmacological properties of different species within this genus, no systematic review is yet available regarding their ethnomedicinal uses in the inflammatory process. This systematic review critically discusses studies on Avicennia species that exhibit anti-inflammatory effects, providing insights and guidance for future research on the plants as potential sources of new dietary supplements or medicinal agents. A literature search was conducted using internet databases such as PubMed, Scopus, Science Direct, and PubPharm, combining keywords like “Avicennia,” “inflammation,” and other related terms, following the PRISMA 2020 guidelines. Research articles were included if they were experimental (in vitro and in vivo) studies on the anti-inflammatory effects of Avicennia species and published in either Bahasa or English between 2012 and 2024. Ten studies on the anti-inflammatory effects of Avicennia species were selected. The five species of the genus Avicennia examined in these studies are A. alba, A. marina, A. schaueriana, A. officinalis, and A. rumphiana. The anti-inflammatory effects of Avicennia were demonstrated by the inhibition of inflammatory cytokine production, nitric oxide production, and inflammation in animal models. Additionally, the secondary metabolites and antioxidant effects of Avicennia species are reported in the selected articles. The phytochemicals of several Avicennia species have been shown to exhibit strong anti-inflammatory effects. Further preclinical studies, including toxicity and pharmacokinetic assessments, are necessary before they can be considered for clinical trials. The genus Avicennia has great potential to be developed into medicinal agents for diseases related to inflammation.